AbbVie Inc. (NYSE:ABBV) Q3 2025 Earnings Call Transcript
Operator: Good morning, and thank you for standing by. Welcome to the AbbVie Third Quarter 2025 Earnings Conference Call. [Operator Instructions] Today's call is also being recorded.
Abbvie Inc. (ABBV)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Lee Munder Capital Group Lee Munder | 143,240 | $33,165,690 | -3% | 1.95% |
| 2. | Polaris Capital Management Bernard Horn | 141,944 | $32,865,714 | -8% | 2.16% |
| 3. | Bailard Inc Thomas Bailard | 45,353 | $10,501,113 | +55% | 0.23% |
| 4. | Beech Hill Partners Paul Cantor, Joseph Weiss, And Will Wurm | 24,222 | $5,608,407 | -3% | 2.62% |
| 5. | HealthInvest Partners AB Anders Hallberg And Carl Bennet | 92,105 | $2,264,052 | +6% | 8.4% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $69.00 | 1,550 | $106,950.00 | 17,644 | 2020-03-20 | Filing | |
| $69.00 | 750 | $51,750.00 | 16,844 | 2020-03-20 | Filing | |
| $67.50 | 800 | $54,000.00 | 16,094 | 2020-03-20 | Filing | |
| $68.18 | 2,200 | $150,004.80 | 15,294 | 2020-03-18 | Filing | |
| $69.00 | 750 | $51,750.00 | 16,844 | 2020-03-30 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $198.42 | 42,370 | $8,407,055.40 | 177,292 | 2025-08-12 | Filing | |
| $198.59 | 10,061 | $1,998,013.99 | 58,247 | 2025-08-05 | Filing | |
| $198.27 | 3,234 | $641,238.89 | 68,308 | 2025-08-05 | Filing | |
| $210.54 | 33,132 | $6,975,611.28 | 53,234 | 2025-03-31 | Filing | |
| $209.49 | 25,700 | $5,383,893.00 | 86,366 | 2025-03-31 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 12,301,919 | $2,848,386,477 | 0.51% | |
| 2. | 8,361,387 | $1,935,995,546 | 0.6% | |
| 3. | 4,495,558 | $1,013,118,952 | 0.89% | |
| 4. | 4,256,071 | $985,450,679 | 0.57% | |
| 5. | 4,025,985 | $932,176,625 | 1.65% |
News See All
Here’s What Drove Baron Health Care Fund to Add AbbVie (ABBV) to Its Portfolio
Baron Funds, an investment management company, released its “Baron Health Care Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here.
Analyst on AbbVie (ABBV): 'Stay Long'
Jason Snipe, the Founder and Chief Investment Officer of Odyssey Capital Advisors, recommended investors to “stay long” AbbVie Inc (NYSE:ABBV) during a recent program on CNBC.
10 Stocks Everyone’s Discussing Amid Latest Earnings Season
Markets are digesting the latest earnings reports to gauge the position of major technology companies and whether they plan to continue to spend a fortune on AI.
Analyst Says He Likes AbbVie (ABBV) Amid 'Attractive' Valuation
“If I’m a little nervous, just a little nervous, I’m going to go with something that’s kind of on the safe side. AbbVie Inc (NYSE:ABBV).
AbbVie Inc. (ABBV): A Bull Case Theory
We came across a bullish thesis on AbbVie Inc. on Disruptive analytics’s Substack by Magnus Ofstad. In this article, we will summarize the bulls’ thesis on ABBV.
10 Stock News You Should Not Miss as Tom Lee Reiterates Bullish Market Outlook Amid AI Catalysts
Markets are getting jittery after JPMorgan CEO Jamie Dimon pointed to potential cracks in the credit markets following a few regional bank earnings.
Cantor Fitzgerald Reaffirms Overweight Rating on AbbVie (ABBV)
On October 14, Cantor Fitzgerald reaffirmed its Overweight rating and $250 price target for AbbVie Inc.
11 Defensive Healthcare Dividend Stocks To Buy Now
US healthcare stocks have been under mounting pressure this year, largely due to policies introduced by the Trump administration.
Cramer’s ‘Absolute Favorite’ AbbVie Rises After Study Completions and Upgrade
At the beginning of this month, AbbVie Inc. (NYSE:ABBV) announced the completion of a key study on ABBV-101’s food interaction and a Phase 2 study of Budigalimab and/or ABBV-382 on HIV.
Hedge Fund Resource Center Billionaire Hedge Funds
